Obesity
From the Journals
What is the dark side of GLP-1 receptor agonists?
“When millions of people are treated with medications like semaglutide, even relatively rare side effects occur in a large number of individuals...
Latest News
Bariatric surgery still best option for some with obesity
“Sometimes we might need to go straight to surgery instead of going through medications first, because it may be the most effective and evidence-...
Commentary
Is metabolically healthy obesity an ‘illusion’?
Now that we have the tools we need, let’s commit to helping our patients achieve true metabolic health.
Conference Coverage
Low-dose aspirin reduces liver fat, inflammation markers
“I’m encouraged by the results with low-dose aspirin, and I think that, given the risk profile, using a lower dose is preferable.”
Latest News
Sleeping beats sitting? What a new study means for your patients
“Our study highlights that replacing sedentary behavior with any other behavior can be beneficial.”
Latest News
‘Love more’: Why doctors should promote social connection
Embracing community and close relationships helps people live longer and be happier.
Latest News
Older adults with type 2 diabetes find weight loss, deprescribing benefits in GLP-1 agonists, small study suggests
GLP-1 agonists may help clinicians manage uncontrolled type 2 diabetes in some older patients without the need for additional glucose-controlling...
Conference Coverage
Weight-loss drugs improve liver measures, too
Body weight reduction of at least 3% within 8 weeks of beginning treatment with either an SLT-2 or GLP-1 agent was associated independently with...
Conference Coverage
Semaglutide ‘a new pathway’ to CVD risk reduction: SELECT
The SELECT trial was “a turning point in the treatment of obesity and a call to action.”
Latest News
MASLD, MASH projected to grow by 23% in the U.S. through 2050
“In the absence of effective treatments, health systems should plan for large increases in the number of liver cancer cases and the need for liver...
Conference Coverage
Newer antiobesity meds lower the body’s defended fat mass
“These medications change [the defended fat mass] to something that is more normal, rather than ‘fixing’ it.”